Elypta operates in the field of cancer detection, specializing in metabolism-based liquid biopsy for early cancer detection.

Elypta

Elypta is developing a metabolism-based liquid biopsy for early cancer detection using machine learning to identify noninvasive biomarkers.

Elypta | 3,084 followers on LinkedIn. Advancing cancer detection | Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively.

Venture Capital - Chief Operating Officer & Investment Director

Jonas Jendi

CEO at Elypta

Karl Bergman

Vice President Research & Development- In Vitro Diagnostics at Elypta

Karin Mattsson

Principal Research Scientist

Davide Tamburro

Meet us at BIO-Europe, November 4-6 in Stockholm, Sweden, to explore cancer diagnostic collaborations and learn about our unique GAGome research platform!

Do not miss the chance to meet our CSO and Founder Francesco G. at #ESMO2024 this year!

Exciting new article in bladder cancer showing the potential of our liquid biopsy platform measuring GAGomes - an important step for noninvasive risk classification of healthy adults. #liquidbiopsy #biomarkers #mced

Join us in welcoming the talented Gaayatri Godbole and Laura Fodor, who will join us as interns in Business Development and Software Engineering this summer! Welcome to the team!

Welcome to the team, Josefin Andersson ! Josefin joins us as a Software Engineer and brings great experience from across the regulated medical device industry. We look forward to advancing cancer detection together! #earlydetection #softwareengineering #newhire #cancerdetection

We are excited to welcome Eva Pisa to the Elypta Board of Directors! She brings a wealth of experience from diagnostics development and commercialization as a previous founder, CEO, having worked in various industry leadership roles and on other Life Science company boards. #lifescience #earlydetection #massspectrometry #liquidbiopsy

Our multicancer detection technology was featured in this review by the National Cancer Institute (NCI) - the only European start-up with level of evidence 3 and in the top 8 start-ups globally for level of evidence among those reviewed by the authors. Proud of our contribution to #mced taking the angle of cancer metabolism. #glycosaminoglycans #liquidbiopsy

Great collaborators stick around! Our Founder and CSO Francesco G. started working with Saeed Dabestani on the AURORAX-0087A study on GAGomes as the first noninvasive biomarkers for renal cell carcinoma 7 years ago! Now, together with our CMO Volker Liebenberg, Dr. , they’re at #EAU24 to present the first data readout to the steering committee - stay tuned for the results! AURORAX-0087A is a EU-cofunded study (Horizon 2020 Grant No 849251), more info here: https://lnkd.in/dsXcdd6q

We are happy to welcome Lucie Gourmet to the team! This brilliant Ph.D. student from the UCL will join our Data Science team as intern. Welcome to Elypta! #elypta

We are excited to announce that interim results from the LEVANTIS-0087A study will be presented at the upcoming 2024 American Association for Cancer Research Annual Meeting. The results indicate the potential of using urine Glycosaminoglycan profiles to identify adults who have an increased risk of developing cancer and therefore may likely benefit from screening, but who are currently excluded from screening based on their age and/or sex. #cancerdetection #earlycancerdetection #multicancerearlydetection

Metric
Company Name	Elypta
Symbol
MSH ID	COM:ELYPTA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	SE
Stage
Employee Count	11
Website	elypta.com
LinkedIn	elypta
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	566
Web Traffic Growth	2.11
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ELYP

COM:ELYPTA

Elypta

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue